Market Update

Life Sciences Software – 2020

October 29, 2020. The onset of the COVID-19 pandemic catalyzed accelerated adoption of frontier technologies in the life sciences software ecosystem, with a heavy focus on virtual trial capabilities. While the pandemic led to a temporary slowdown in transaction activity for a few weeks in early 2020, the fundamental technology shifts in the life sciences market have sparked a recent resurgence of M&A and investment appetite. We foresee strong continued interest in this sector in the coming months.

MPG actively tracks the life sciences software landscape and have noticed a number of market dynamics:

  • The onset of COVID-19 has forced market incumbents and challengers to recognize the strategic imperative of virtual trial technologies, paving the way for eClinical disruption
  • Passing of the final milestone in the SEND timeline will pave the way for conformity in pre-clinical submissions and provide further opportunity for pre-clinical vendors
  • Patient recruitment and engagement is evolving from a site-based “hands-on” activity to a more efficient, scalable and non-traditional digital-first approach
  • The Dassault / Medidata transaction led to a broader consolidation play in the eClinical market driven by both strategic acquirers and financial sponsors

About The Author

Rohan Khanna
Managing Director

Jonathan Adler
Managing Director

Get in touch with us

Contact Us

  • Hidden
  • This field is for validation purposes and should be left unchanged.